What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications

Ramírez-Mejía, Mariana M.; Méndez-Sánchez, Nahum

doi:10.1007/s11901-023-00620-9

Cited by 6 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MASLD is characterized by the presence of liver disease accompanied by at least one of the five cardiometabolic risk factors, including a high body mass index (BMI), raised blood sugar, elevated blood pressure, hypertriglyceridemia, and low high-density lipoprotein cholesterol levels [ 5 , 6 ]. It encompasses both simple steatosis, which typically follows a more benign course, and metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis, NASH), predisposing patients to fibrosis and/or HCC.…”

Section: Introductionmentioning

confidence: 99%

MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options

Shi,

Taherifard,

Saeed

et al. 2024

CIMB

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents a significant burden on global healthcare systems due to its considerable incidence and mortality rates. Recent trends indicate an increase in the worldwide incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) and a shift in the etiology of HCC, with MASLD replacing the hepatitis B virus as the primary contributor to new cases of HCC. MASLD-related HCC exhibits distinct characteristics compared to viral HCC, including unique immune cell profiles resulting in an overall more immunosuppressive or exhausted tumor microenvironment. Furthermore, MASLD-related HCC is frequently identified in older age groups and among individuals with cardiometabolic comorbidities. Additionally, a greater percentage of MASLD-related HCC cases occur in noncirrhotic patients compared to those with viral etiologies, hindering early detection. However, the current clinical practice guidelines lack specific recommendations for the screening of HCC in MASLD patients. The evolving landscape of HCC management offers a spectrum of therapeutic options, ranging from surgical interventions and locoregional therapies to systemic treatments, for patients across various stages of the disease. Despite ongoing debates, the current evidence does not support differences in optimal treatment modalities based on etiology. In this study, we aimed to provide a comprehensive overview of the current literature on the trends, characteristics, clinical implications, and treatment modalities for MASLD-related HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options

Shi,

Taherifard,

Saeed

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

Metabolic dysfunction associated fatty liver disease in healthy weight individuals

Méndez-Sánchez,

Brouwer,

Lammert

et al. 2024

Hepatol Int

View full text Add to dashboard Cite

Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD is not exclusive to obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into the genetic, lifestyle, and dietary factors that contribute to the development of MAFLD in this population. This shift in perspective requires reconsideration of preventive strategies, diagnostic criteria and therapeutic approaches tailored to address the unique characteristics of MAFLD healthy weight individuals. It also underscores the importance of widespread awareness and education, within the medical community and among the general population, to promote a more inclusive understanding of liver metabolic disorders. With this review, we aim to provide a comprehensive exploration of MAFLD in healthy weight individuals, encompassing epidemiological, pathophysiological, and clinical aspects.

show abstract

Mechanisms of Metal-Induced Hepatic Inflammation

Subramaniam,

Mann

2024

Curr Envir Health Rpt

View full text Add to dashboard Cite

What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications

Cited by 6 publications

References 58 publications

MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options

MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options

Metabolic dysfunction associated fatty liver disease in healthy weight individuals

Mechanisms of Metal-Induced Hepatic Inflammation

Contact Info

Product

Resources

About